Good MorningThe selloff in equities resumed on Thursday as traders brace for what could be an historic PCE price index. Although the index is expected to decelerate on a YOY basis it is expected to remain high and at a level that confirms the latest twist in the FOMC outlook. The twist is that the FOMC slowed the rate hike pace but upped its expectations for both inflation and peak interest rates.
Thursday’s candle is a warning to the market. Investors hoping for a Santa Claus Rally should be cautious. The market may rise next week simply because of a lack of volume and the "underlying bid". In this scenario, any upswing in prices will likely be met by selling that drives the index down to a new low Featured: 25 candidates screened. 5 made it. (Ad) 
|
Technology | |
Well, it was fun while it lasted. Traders had some holiday fun with Palantir Technologies Inc. (NYSE: PLTR) stock a few days before the Christmas holiday. On December 21, PLTR shares went up 5% on the news that Palantir was awarded a multi-million deal with the United Kingdom's Ministry of Defense... Read the Full Story |
|
From Our Partners | | A 20-minute read could change how you approach your next options trade. Chris Pulver is giving away his guide, Right About The Market, Wrong About The Money, free of charge.
Built from two decades of trading experience, the guide tackles a common problem: losing a trade even when your market call was correct.
No cost, no catch, just a packed resource for options traders who want a sharper edge. | | Click here to get your free copy of the guide |
|
Industrials | |
You may think of equipment makers Caterpillar Inc. (NYSE: CAT) and Deere & Company (NYSE: DE) as literally moving slowly, but these heavy equipment stocks outran the S&P 500 throughout 2022 and pulled into a sprint to end the year.
Despite its name, Caterpillar hasn’t exactly been c... Read the Full Story |
|
Consumer Discretionary | |
Mullen Automotive, Inc. (NASDAQ: MULN) stock is up nearly 4% (3.95%) in midday trading on news that the company's first I-GO™ vehicles have arrived in Europe. The I-GO™ is an urban commercial delivery vehicle purposefully designed to meet the space constraints in dense cities throughou... Read the Full Story |
|
From Our Partners | | Each morning, the Wave Software scans the market for stocks quietly building momentum over days or weeks, then narrows the list to a single name showing signs of an imminent move.
From there, it outlines specific options criteria designed to match that potential move, giving traders a complete setup before the market opens.
No guesswork, no scanning countless charts, just one focused opportunity to evaluate each day. | | See how the Wave Software pinpoints daily trade opportunities before 9 am. |
|
Markets | |
What is dividend yield? It’s an excellent question for budding investors.
Dividends are one of only two reasons to own stocks and the only reason you can rely on stock to any extent. Dividends are the payments publicly traded companies pay to their investors, and the dividend yield measure... Read the Full Story |
|
Technology | |
As temperatures drop throughout the U.S., sunshine and warmth may seem like distant dreams. But for shareholders of top-performing solar-energy stocks such as Enphase Energy Inc. (NASDAQ: ENPH), SolarEdge Technologies Inc. (NASDAQ: SEDG), and First Solar Inc. (NASDAQ: FSLR), those brighter days ma... Read the Full Story |
|
From Our Partners | | Unitree's IPO grabbed headlines, but a handful of already-public robotics companies have been quietly delivering results that look nothing like hype.
One robotics-and-testing firm grew quarterly revenue from $686 million to $1.282 billion year over year and broke out above a $422.11 buy point. A warehouse robotics company exited the quarter with a $22.7 billion backlog and $2.0 billion in cash with no debt. A robotic surgery leader placed 431 systems in a single quarter. | | Get the free robotics stock report now. |
|
Consumer Discretionary | |
On a day when the broader market soared over 500 points, Lucid Group, Inc. (NASDAQ: LCID) was a notable laggard. Shares of LCID stock fell by less than one percent. But it continues the downward trend for the stock, down 30% in the last month and over 80% in 2022.
One sore spot for investors is ... Read the Full Story |
|
Markets | |
The institutions have helped to indicate a bottom in Rite Aid Corporation (NYSE: RAD) shares, not so much because of their buying but the opposite. The institutions had been heavy buyers all year despite the downturn in the price action, but that changed in Q4. In Q4 a broad array of sell-side ins... Read the Full Story |
|
Industrials | |
Shares of Fedex Corporation (NYSE: FDX) are up over 5% the day after the company surprised investors with a beat on the bottom line. The $3.18 earnings per share (EPS) the company delivered was over 12% higher than analysts’ expectations for EPS of $2.82.
That’s the good news. The ba... Read the Full Story |
|
Healthcare | |
Viking Therapeutics (NASDAQ: VKTX) develops novel therapeutics for patients suffering from disorders related to the metabolic and endocrine systems. Recently, their stock soared for a somewhat unique reason: the success of a peer. While they can certainly develop their own promising products, thei... Read the Full Story |
|
Consumer Discretionary | |
NIKE, Inc. (NYSE: NKE) stock is set up for a reversal, and the 2023 outlook may drive it. The company just reported earnings for CQ4 and not only beat on the top and bottom lines but showed significant improvement in its inventory position. This is important because bloating inventories and the ne... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California. | | View Today's Stock Pick |
|
